Why has Cencora (COR) risen by 2% following its most recent earnings announcement?

Cencora's Recent Performance and Earnings Overview

Over the past month, Cencora (COR) has seen its stock price rise by approximately 2%, outpacing the S&P 500 index. Investors are now considering whether this upward momentum will persist as the company approaches its next earnings announcement, or if a correction is on the horizon. To better understand the factors influencing Cencora's recent results, let's review its latest earnings report and subsequent analyst reactions.

First Quarter Results: Earnings and Margins

For the fiscal first quarter of 2026, Cencora posted adjusted earnings per share of $4.08, slightly exceeding the Zacks Consensus Estimate of $4.07. This figure marked a 9.4% increase compared to the same period last year. On a GAAP basis, earnings per share reached $2.87, representing a 14.8% year-over-year improvement.

Revenue Breakdown

The company generated $85.93 billion in revenue during the quarter, reflecting a 5.5% rise from the previous year and closely matching analyst expectations.

Segment Performance

• U.S. Healthcare Solutions:

  This segment reported revenues of $76.2 billion, up 5% year over year. Growth was driven by higher unit volumes, particularly in GLP-1 drugs and specialty products. Operating income for the segment reached $831.3 million, a 21% increase, supported by greater gross profits from increased sales and the acquisition of RCA in January 2025, though higher operating expenses partially offset these gains.

• International Healthcare Solutions:

  Including Alliance Healthcare, World Courier, Innomar, and Profarma Specialty, this segment delivered $7.6 billion in revenue, up 7.6% year over year. On a reported basis, revenue grew 9.6%, and 6.2% at constant currency. Operating income declined to $142.2 million, down 13.9% reported and 17% at constant currency, mainly due to reduced profitability in global specialty logistics and consulting services.

Profitability and Margins

Adjusted gross profit reached $3 billion, up 18.1% from the prior year. The adjusted gross margin improved to 3.48%, an increase of 37 basis points. Adjusted operating income was $1.1 billion, up 11.9%, with the operating margin expanding to 1.24%, up 8 basis points.

Financial Position

At the end of the quarter, Cencora held $1.75 billion in cash and equivalents, down from $4.36 billion in the previous quarter. Net cash used in operating activities was $2.31 billion, compared to $2.72 billion a year earlier.

Dividend Announcement

The board declared a quarterly dividend of $0.60 per share, payable on March 2, 2026, to shareholders of record as of February 13, 2026.

Updated Fiscal 2026 Guidance

• Adjusted earnings per share are expected to range between $17.45 and $17.75.
• Total revenue growth is now forecasted at 7%-9%, up from the previous estimate of 5%-7%.
• Both U.S. and International Healthcare Solutions segments are projected to grow revenues by 7%-9%.
• Adjusted operating income is anticipated to increase by 11.5%-13.5%, compared to earlier guidance of 8%-10%.
• Operating income for U.S. Healthcare Solutions is expected to rise 14%-16%, while International Healthcare Solutions is projected to grow 5%-8%, both reported and at constant currency.

Estimate Trends and Stock Ratings

Over the past month, analyst estimates for Cencora have generally moved lower, indicating a more cautious outlook. The stock currently holds a Zacks Rank #3 (Hold), suggesting expectations for performance in line with the broader market in the coming months.

VGM Scores

• Growth Score: F
• Momentum Score: F
• Value Score: B (placing it among the top 40% for value investors)
• Overall VGM Score: F

If you prefer a diversified investment approach, the overall VGM Score is particularly relevant.

Industry Comparison: HCA Healthcare

Cencora operates within the Zacks Medical Services sector. Over the last month, HCA Healthcare (HCA), another industry member, saw its stock rise by 4%. HCA reported quarterly revenues of $19.51 billion, up 6.7% year over year, and earnings per share of $8.01, compared to $6.22 a year earlier. For the current quarter, HCA is expected to deliver earnings of $7.18 per share, an 11.3% increase year over year, with the consensus estimate rising by 0.2% over the past 30 days. HCA also holds a Zacks Rank #3 (Hold) and boasts a VGM Score of A.

Featured Stock Picks

Zacks' research team has identified five stocks with strong potential to double in value in the coming months. Among these, Director of Research Sheraz Mian highlights a satellite communications company poised for significant growth as the space industry expands toward a trillion-dollar market. Analysts anticipate a major revenue surge in 2025. While not all picks achieve outsized gains, this selection could outperform previous top performers like Hims & Hers Health, which rose over 200%.